Telesis Bio Stock Today
| TBIO Stock | USD 0.05 0.04 284.62% |
PerformanceSolid
| Odds Of DistressModerate
|
Telesis Bio is selling at 0.05 as of the 10th of January 2026; that is 284.62% up since the beginning of the trading day. The stock's open price was 0.013. Telesis Bio has over 57 % chance of experiencing financial distress in the next 2 years of operation, but had a somewhat solid returns during the last 90 days. The performance scores are derived for the period starting the 12th of October 2025 and ending today, the 10th of January 2026. Click here to learn more.
Translate Bio, Inc., a clinical-stage messenger RNA therapeutics company, develops medicines to treat diseases caused by protein or gene dysfunction. The company was founded in 2011 and is headquartered in Lexington, Massachusetts. Translate Bio operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. The company has 1.77 M outstanding shares of which 29.7 K shares are at this time shorted by private and institutional investors with about 0.42 trading days to cover. More on Telesis Bio
Moving against Telesis Pink Sheet
Follow Valuation Odds of Bankruptcy
Check how we calculate scores
Telesis Pink Sheet Highlights
| CEO, President | Eric Esser |
| Business Concentration | Health Care, Health Care Equipment & Supplies, Biotechnology, Healthcare (View all Sectors) |
Telesis Bio [TBIO] is a Pink Sheet which is traded between brokers as part of OTC trading. The company currently falls under 'Nano-Cap' category with a current market capitalization of 5.73 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Telesis Bio's market, we take the total number of its shares issued and multiply it by Telesis Bio's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Telesis Bio conducts business under Health Care Equipment & Supplies sector and is part of Health Care industry. The entity has 1.77 M outstanding shares of which 29.7 K shares are at this time shorted by private and institutional investors with about 0.42 trading days to cover.
Telesis Bio currently holds about 654.75 M in cash with (34.67 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 8.7, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Telesis Bio Probability Of Bankruptcy
Ownership AllocationTelesis Bio maintains significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares.
Check Telesis Ownership Details
Telesis Bio Risk Profiles
| Mean Deviation | 57.78 | |||
| Semi Deviation | 18.8 | |||
| Standard Deviation | 129.56 | |||
| Variance | 16786.35 |
Telesis Stock Against Markets
Be your own money manager
Our tools can tell you how much better you can do entering a position in Telesis Bio without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Positions Ratings Now
Positions RatingsDetermine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance |
| All Next | Launch Module |
Telesis Bio Corporate Management
| Decky MBA | Senior Development | Profile | |
| Laura MBA | Vice Culture | Profile | |
| Jen Carroll | Vice Relations | Profile | |
| Laurence Warden | Senior Instrumentation | Profile | |
| William Kullback | Chief Officer | Profile |
Other Information on Investing in Telesis Pink Sheet
Telesis Bio financial ratios help investors to determine whether Telesis Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Telesis with respect to the benefits of owning Telesis Bio security.